- Home
- HL vs CORT Comparison
HL vs CORT Comparison
Compare HL & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HL | CORT |
|---|---|---|
| Founded | 1891 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 7.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HL | CORT |
|---|---|---|
| Price | $18.65 | $88.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $11.14 | ★ $139.00 |
| AVG Volume (30 Days) | ★ 17.8M | 663.7K |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | ★ 0.08% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.31 | ★ 0.87 |
| Revenue | ★ $1,224,563,000.00 | $741,172,000.00 |
| Revenue This Year | $43.45 | $23.79 |
| Revenue Next Year | $15.89 | $40.97 |
| P/E Ratio | ★ $60.76 | $99.75 |
| Revenue Growth | ★ 45.62 | 17.92 |
| 52 Week Low | $4.46 | $49.00 |
| 52 Week High | $20.19 | $117.33 |
Technical Indicators
Market Signals| Indicator | HL | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 67.24 | 68.54 |
| Support Level | $15.84 | $81.31 |
| Resistance Level | $17.48 | $87.19 |
| Average True Range (ATR) | 1.11 | 2.86 |
| MACD | 0.20 | 0.74 |
| Stochastic Oscillator | 79.00 | 93.81 |
Price Performance
Historical ComparisonAbout HL Hecla Mining Company
Hecla Mining Co produces and explores silver, gold, zinc, and other metals. The operating business segments are Greens Creek, Lucky Friday, Keno Hill, and Casa Berardi. It generates maximum revenue from the Greens Creek segment. Geographically, It operates in Canada, the United States, and Mexico, and it derives a majority of its revenue from the United States.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.